Clinical and genetic spectrum of SCN2A-associated episodic ataxia

Schwarz, N., Bast, T., Gaily, E., Golla, G., Gorman, K. M., , Hahn, A., Hukin, J., King, M., Korff, C., Miranda, M. J., Møller, R. S., Neubauer, B., , Smol, T., Striano, P., Stroud, B., Vaccarezza, M., Kluger, G., Lerche, H., & Fazeli, W. (2019) Clinical and genetic spectrum of SCN2A-associated episodic ataxia. European Journal of Paediatric Neurology, 23(3), pp. 438-447.

View at publisher

Description

Background: Pathogenic variants in SCN2A are associated with various neurological disorders including epilepsy, autism spectrum disorder and intellectual disability. Few reports have recently described SCN2A-associated episodic ataxia (EA). Our study identifies its broader clinical and genetic spectrum, and describes pharmacological approaches.

Results: We report 21 patients with SCN2A-associated EA, of which 9 are unpublished cases. The large majority of patients present with epileptic seizures (18/21, 86%), often starting within the first three months of life (12/18, 67%). In contrast, onset of episodic ataxia ranged from 10 months to 14 years of age. The frequency of EA episodes ranged from brief, daily events up to 1–2 episodes per year each lasting several weeks. Potential triggers include minor head traumas and sleep deprivation. Cognitive outcome is favorable in most patients with normal or mildly impaired cognitive development in 17/21 patients (81%). No clear genotype–phenotype correlations were identified in this cohort. However, two mutational hotspots were identified, i.e. 7/21 patients (33%) harbor the identical pathogenic variant p.A263V, whereas 5/21 (24%) carry pathogenic variants that affect the S4 segment and its cytoplasmic loop within the domain IV. In addition, we identified six novel pathogenic variants in SCN2A. While acetazolamide was previously reported as beneficial in SCN2A-associated EA in one case, our data show a conflicting response in 8 additional patients treated with acetazolamide: three of them profited from acetazolamide treatment, while 5/8 did not.

Conclusions: Our study describes the heterogeneous clinical spectrum of SCN2A-associated EA, identifies two mutational hotspots and shows positive effects of acetazolamide in about 50%.

Impact and interest:

51 citations in Scopus
44 citations in Web of Science®
Search Google Scholar™

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 202433
Item Type: Contribution to Journal (Journal Article)
Refereed: Yes
ORCID iD:
Griffiths, L. R.orcid.org/0000-0002-6774-5475
Smith, R. A.orcid.org/0000-0003-4825-2461
Measurements or Duration: 10 pages
Keywords: Acetazolamide, Epilepsy, Episodic ataxia, SCN2A
DOI: 10.1016/j.ejpn.2019.03.001
ISSN: 1090-3798
Pure ID: 63507594
Divisions: Past > Institutes > Institute of Health and Biomedical Innovation
Funding Information: N.S. was in part supported from the intramural research funding program of the Faculty of Medicine Tübingen (Fortüne 2381-0-0 ). J.H. conducted her work within the GARD study (protocol H09-01228) and TIDEX Study (protocol H12-00067).
Copyright Owner: 2019 European Paediatric Neurology Society
Copyright Statement: This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au
Deposited On: 23 Jul 2020 13:52
Last Modified: 11 Nov 2026 07:48